Skip to main content

Advertisement

Table 1 Demographics for all treated patients as well as those completing treatment

From: A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome

  All treated patients (N = 20) Patients completing week 12 (N = 18)
Age (years): mean (SD) 10.40 (3.88) 10.78 (3.86)
 Range (min, max) 6–17 6–17
BMI (kg/m2): mean (SD) 19.34 (5.75) 19.50 (5.97)
 Range (min, max) 12.60–35.00 12.60–35.00
Sex: frequency (%)
 Male 15 (75.00%) 14 (77.80%)
 Female 5 (25.00%) 4 (22.20%)
Ethnicity: frequency (%)
 White, not Hispanic or Latino 18 (90.00%) 16 (88.90%)
 Other (Middle Eastern) 2 (10.00%) 2 (11.10%)